Safety and immunogenicity of the live attenuated intranasal pertussis vaccine BPZE1: a phase 1b, double-blind, randomised, placebo-controlled dose-escalation study

RCT (n=120) found that BPZE1 was safe, well-tolerated, induced high colonisation rate in adults, and was immunogenic at all doses. Findings justify further clinical development for use as priming vaccine for neonates, booster vaccine for adolescents and adults, or both.


The Lancet Infectious Diseases